Up a level |
Muñoz-Martínez, Sergio; Sapena, Victor; Forner, Alejandro; Bruix, Jordi; Sanduzzi-Zamparelli, Marco; Ríos, José; Bouattour, Mohamed; El Kassas, Mohamed; Leal, Cassia Regina Guedes; Mocan, Tudor; Nault, Jean-Charles; Alves, Rogerio Camargo Pinheiro; Reeves, Helen L; da Fonseca, Leonardo; García-Juárez, Ignacio; Pinato, David J; Varela, María; Alqahtani, Saleh A; Alvares-da-Silva, Mario Reis; Bandi, Juan C; ... (2022). Outcome of liver cancer patients with SARS-CoV-2 infection. Liver international, 42(8), pp. 1891-1901. Wiley 10.1111/liv.15320
Scheiner, Bernhard; Pomej, Katharina; Kirstein, Martha M; Hucke, Florian; Finkelmeier, Fabian; Waidmann, Oliver; Himmelsbach, Vera; Schulze, Kornelius; von Felden, Johann; Fründt, Thorben W; Stadler, Marc; Heinzl, Harald; Shmanko, Kateryna; Spahn, Stephan; Radu, Pompilia; Siebenhüner, Alexander R; Mertens, Joachim C; Rahbari, Nuh N; Kütting, Fabian; Waldschmidt, Dirk-Thomas; ... (2022). Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. Journal of hepatology, 76(2), pp. 353-363. Elsevier 10.1016/j.jhep.2021.09.035
Muñoz-Martínez, Sergio; Sapena, Victor; Forner, Alejandro; Nault, Jean-Charles; Sapisochin, Gonzalo; Rimassa, Lorenza; Sangro, Bruno; Bruix, Jordi; Sanduzzi-Zamparelli, Marco; Hołówko, Wacław; El Kassas, Mohamed; Mocan, Tudor; Bouattour, Mohamed; Merle, Philippe; Hoogwater, Frederik J H; Alqahtani, Saleh A; Reeves, Helen L; Pinato, David J; Giorgakis, Emmanouil; Meyer, Tim; ... (2021). Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP reports, 3(3), p. 100260. Elsevier 10.1016/j.jhepr.2021.100260
Pfister, Dominik; Núñez, Nicolás Gonzalo; Pinyol, Roser; Govaere, Olivier; Pinter, Matthias; Szydlowska, Marta; Gupta, Revant; Qiu, Mengjie; Deczkowska, Aleksandra; Weiner, Assaf; Müller, Florian; Sinha, Ankit; Friebel, Ekaterina; Engleitner, Thomas; Lenggenhager, Daniela; Moncsek, Anja; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; ... (2021). NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 592(7854), pp. 450-456. Springer Nature 10.1038/s41586-021-03362-0